Treatment for Early Memory Loss

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-06-30

Study Completion Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

NCT03090516

Alzheimer's

UNKNOWN PHASE2/PHASE3

Memory and Mental Health in Aging

NCT00043589

Memory Disorders

COMPLETED NA

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173

Alzheimer Disease

COMPLETED PHASE3

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979

Parkinson Disease

COMPLETED PHASE4

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

NCT00483028

Alzheimer's Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cognition involves important thinking processes such as perception, learning, and reasoning. There are currently no definitive treatments for cognitive deterioration. This study focuses on elderly individuals with MCI because people at a pre-dementia stage may sustain the greatest and most lasting benefit from cognitive-enhancing agents.

Patients receive either donepezil or placebo for the first 6 months of the study. In the second 6 months of the study, patients are randomized to receive either donepezil plus GBE or donepezil alone. Positron Emission Tomography (PET), which provides a color-coded image of the brain's blood flow in a particular area, is used to assess brain activity during memory tasks. A PET scan is performed at study entry, 6 months, and 1 year. A vasodilator (a drug that dilates the blood vessels) is administered during the PET imaging procedure to determine whether vascular disease affects memory function. A magnetic resonance imaging (MRI) scan is also taken to view the brain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognition Disorders Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Donepezil

Intervention Type DRUG

Ginkgo Biloba Extract

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Display impairment on at least 2 of 3 memory tests
* Meet the following criteria for mild cognitive impairment: subjective complaint of memory problems; no impairment in activities of daily living; general cognitive function in the normal age-adjusted range; abnormal memory function for age; and lacking full DSM criteria for dementia

Exclusion Criteria

* Have a history of major neurological, metabolic, psychiatric or cardiovascular disease (patients with a history of non-CNS oncologic disease treated surgically and currently in remission will not be excluded)
* Have a cerebrovascular condition
* Abuse alcohol or drugs
* Have renal or hepatic disease, diabetes mellitus, gout, or adrenocortical insufficiency
* Are sensitive to carbonic anhydrase inhibitors, antibacterial sulfonamides, thiazide diuretics, or other sulfonamide-derivative diuretics
* Have taken donepezil or GBE products prior to enrollment
* Have taken medications, including herbal agents (exceptions will be made for routine health maintenance medications such as alendronate \[Fosamax\] for osteoporosis, vitamin therapy \[not to exceed 200 percent RDA for any particular vitamin\], thyroid replacement therapy, hormone replacement, and ophthalmic medications for glaucoma and other eye disorders)

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes